Evidence map›Paper›PMID 36696030›Full record

ReviewCerebellum (London, England)2024

Two New Families and a Literature Review of ELOVL4-Associated Spinocerebellar Ataxia Type 34.

Masahiro Nishide, Kathleen Le Marquand, Mark R Davis, Gábor M Halmágyi, Avi Fellner, Ramesh K Narayanan, Marina L Kennerson, Stephen W Reddel, Lisa Worgan, Peter K Panegyres and 1 more

Open access · hybridAbstract readReview
In one paragraph

Review in Cerebellum (London, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 7 institutions in 3 countries.

Masahiro NishideSydney Medical School, University of Sydney, Camperdown, NSW, 2050, Australia.
Kathleen Le MarquandClinical Genetics Service, Royal Prince Alfred Hospital, Camperdown, NSW, 2050, Australia.
Mark R DavisDepartment of Diagnostic Genomics, Path West Laboratory Medicine, QEII Medical Centre, Hospital Avenue, Nedlands, WA, Australia.
Gábor M HalmágyiNeurology Department, Royal Prince Alfred Hospital, Camperdown and the University of Sydney, Sydney, NSW, 2050, Australia.
Avi FellnerGarvan Institute of Medical Research, Darlinghurst, NSW, 2010, Australia.
Ramesh K NarayananSydney Medical School, University of Sydney, Camperdown, NSW, 2050, Australia.
Marina L KennersonSydney Medical School, University of Sydney, Camperdown, NSW, 2050, Australia.
Stephen W ReddelDepartment of Neurology, Concord Repatriation General Hospital, Concord, NSW, 2139, Australia.
Lisa WorganClinical Genetics Service, Royal Prince Alfred Hospital, Camperdown, NSW, 2050, Australia.
Peter K PanegyresNeurodegenerative Disorders Research Pty Ltd, West Perth, WA, 6005, Australia.
Kishore R KumarSydney Medical School, University of Sydney, Camperdown, NSW, 2050, Australia. kkum4618@uni.sydney.edu.au.
University of Sydney · AUConcord Repatriation General Hospital · AURoyal Prince Alfred Hospital · AUAnzac Research Institute · AUQueen Elizabeth II Medical Centre · AURabin Medical Center · ILUniversity of Western Australia · AU

Funding

ChimeraX -- Next Generation Visualization and Analysis Software for Multiscale ModelingR01GM129325 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI FERRIN, THOMAS E · 2018 to 2025
$5.2M
NIGMS NIH HHS R01 GM129325
6 · The paper itself

Abstract

Autosomal dominant variants in ELOVL4 cause spinocerebellar ataxia type 34 (SCA34; ATX-ELOVL4), classically associated with a skin condition known as erythrokeratoderma. Here, we report a large Italian-Maltese-Australian family with spinocerebellar ataxia. Notably, while there were dermatological manifestations (eczema), erythrokeratoderma was not present. Using a next-generation sequencing panel, we identified a previously reported ELOVL4 variant, NM_022726.4: c.698C > T p.(Thr233Met). The variant was initially classified as a variant of uncertain significance; however, through segregation studies, we reclassified the variant as likely pathogenic. We next identified an individual from another family (Algerian-Maltese-Australian) with the same ELOVL4 variant with spinocerebellar ataxia but without dermatological manifestations. We subsequently performed the first dedicated literature review of ELOVL4-associated ataxia to gain further insights into genotype-phenotype relationships. We identified a total of 60 reported cases of SCA34 to date. The majority had gait ataxia (88.3%), limb ataxia (76.7%), dysarthria (63.3%), and nystagmus (58.3%). Of note, skin lesions related to erythrokeratoderma were seen in a minority of cases (33.3%). Other extracerebellar manifestations included pyramidal tract signs, autonomic disturbances, retinitis pigmentosa, and cognitive impairment. For brain MRI data, cerebellar atrophy was seen in all cases (100%), whereas the hot cross bun sign (typically associated with multiple system atrophy type C) was seen in 32.4% of cases. Our family study and literature review highlight the variable phenotypic spectrum of SCA34. Importantly, it shows that erythrokeratoderma is not found in most cases and that, while a dermatological assessment may be helpful in these patients, SCA34 diagnosis should be considered irrespective of dermatological manifestations.

Indexed as

Cerebellar AtaxiaSkin Diseases, GeneticSpinocerebellar AtaxiasAtaxiaEye ProteinsHumansMembrane ProteinsELOVL4 protein, humanEye ProteinsMembrane ProteinsELOVL4ErythrokeratodermaMedical geneticsNext-generation sequencingSpinocerebellar ataxia type 34 (SCA34)

Identifiers

PMID36696030
PMCPMC10864522
OpenAlexW4317931239

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.